San Diego-based Receptos has snagged a deal to put one of AbbVie's respiratory drugs through a Phase II study, taking on the risk of mid-stage work while securing an option deal that allows AbbVie the right to step back in if the therapy looks promising enough to take it forward into Phase III.
The huge late-stage study that is seeking to determine once and for all if Merck's combo cholesterol drug Vytorin actually works and is safe will run its full course now that an independent safety board has signed off following a review of the data.
GlaxoSmithKline's move to rehabilitate its reputation with a commitment to open up its data vault on approved drugs has won widespread acclaim, and at least limited support from Roche. Read more >>
Roche is reporting encouraging results from a mid-stage study of inclacumab, saying the data demonstrated a clear clinical benefit by reducing inflammation during angioplasty.
Canada's Aeterna Zentaris took another bad hit today after it announced that it is scuttling a Phase III study of perifosine for relapsed/refractory multiple myeloma. The move came after the drug safety monitoring board decided that there was little to no chance the therapy would meet the hurdle for progression free survival.
As many as 2,868 people have died in Indian clinical trials over the past 7 years, and sponsors and CROs have paid out compensation in just 45 of those instances, according to India's Business Standard .
If at first you don't succeed in Phase III, try, try again. Only enroll lots more patients and improve the trial design. That was The Medicines Company's strategy when it opted to pay for a third pivotal study of the blood thinner cangrelor.
Novartis has talked up the prospects of its typhoid vaccine candidate after completing Phase II safety studies. A wider rollout is now being considered as Novartis pushes to develop a vaccine to eliminate a disease that still kills 200,000 people a year.
Medivir has posted a stellar snapshot of interim data from its Phase IIa study of a combo hep C treatment that adds Gilead's hot property--GS-7977--with the Swedish biotech's simeprevir (TMC435), which is partnered with Johnson & Johnson.
Covance is stepping up its personalized medicine services, teaming up with the biomarker-focused M2Gen to better identify ideal patients for oncology drug trials.